Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HDAC-42 × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

Temozolomide 10 Lomustine 6 Radiotherapy 4 Etoposide 3 Carboplatin 3 Bevacizumab 3 vocimagene amiretrorepvec 2 Vincristine 2 Radiation 2 Magnetic Resonance Spectroscopy 2 Gefitinib 2 veliparib 1 trofosfamide 1 trametinib 1 tozuleristide 1 regorafenib 1 dabrafenib 1 cobimetinib 1 carbon-11 acetate 1 antisecretory factor 1 Vorinostat 1 Vemurafenib 1 Thiotepa 1 Sunitinib 1 Standard of Care 1 Saline Solution 1 Procarbazine 1 Pregabalin 1 Minocycline 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡